Why Mylan Is Poised to Keep Popping

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic pharmaceutical company Mylan (NASDAQ: MYL  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Mylan and see what CAPS investors are saying about the stock right now.

Mylan facts

Headquarters (founded)

Canonsburg, Pa. (1961)

Market Cap

$11.4 billion



Trailing-12-Month Revenue

$6.8 billion


CEO Heather Bresch
CFO John Sheehan

Return on Equity (average, past 3 years)



$409.5 million / $5.7 billion


Abbott Labs
Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 569 members who have rated Mylan believe the stock will outperform the S&P 500 going forward.

Earlier this year, one of those Fools, brenoboyle, succinctly summed up the bull case for our community:

Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and [less than] 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Mylan may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2341778, ~/Articles/ArticleHandler.aspx, 5/24/2016 4:09:45 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian D. Pacampara, CFA

Brian has been writing for The Fool since 2006, and currently covers consumer goods stocks. He has a B.A. from Western University (Ontario, Canada) and holds the CFA designation.

Today's Market

updated Moments ago Sponsored by:
DOW 17,716.80 223.87 1.28%
S&P 500 2,076.50 28.46 1.39%
NASD 4,864.01 98.22 2.06%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2016 3:53 PM
MYL $42.42 Up +1.21 +2.94%
Mylan CAPS Rating: *****
ABT $38.02 Up +0.65 +1.73%
Abbott Laboratorie… CAPS Rating: ****
TEVA $51.98 Up +0.76 +1.49%
Teva Pharmaceutica… CAPS Rating: *****